share_log

Results: Science Applications International Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts

Results: Science Applications International Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts

結果:科學應用國際公司超出盈利預期,分析師現在有了新的預測
Simply Wall St ·  12/08 08:08

Science Applications International Corporation (NASDAQ:SAIC) just released its latest third-quarter results and things are looking bullish. The company beat forecasts, with revenue of US$2.0b, some 2.3% above estimates, and statutory earnings per share (EPS) coming in at US$2.13, 24% ahead of expectations. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

Science Applications International公司(納斯達克: SAIC)剛發佈了最新的第三季度業績,情況看好。公司超過了預測,營業收入爲20億美元,比預期高出2.3%,每股收益(EPS)爲2.13美元,比預期高出24%。分析師通常會在每次業績後更新他們的預測,我們可以從他們的估計中判斷他們對公司的看法是否改變,或者是否有需要注意的新問題。因此,我們收集了最新的業績後的法定共識預測,以了解接下來可能會發生什麼。

big
NasdaqGS:SAIC Earnings and Revenue Growth December 8th 2024
NasdaqGS: SAIC盈利和營收增長2024年12月8日

Taking into account the latest results, the current consensus from Science Applications International's nine analysts is for revenues of US$7.60b in 2026. This would reflect an okay 3.1% increase on its revenue over the past 12 months. Per-share earnings are expected to expand 15% to US$7.11. Before this earnings report, the analysts had been forecasting revenues of US$7.59b and earnings per share (EPS) of US$7.13 in 2026. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

考慮到最新的結果,科學應用國際公司的九名分析師目前一致預計2026年的營收爲76億美元。這將反映出其營收在過去12個月中增長了3.1%。預計每股收益將增長15%,達到7.11美元。在此次業績之前,分析師們一直在預測2026年的營收爲75.9億美元,每股收益(EPS)爲7.13美元。因此,很明顯,儘管分析師已經更新了他們的預測,但在最新的結果公佈後,業務的預期並未發生重大變化。

The analysts reconfirmed their price target of US$143, showing that the business is executing well and in line with expectations. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Science Applications International at US$155 per share, while the most bearish prices it at US$124. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.

分析師重申了對143美元的目標價,顯示業務的表現良好,符合預期。然而,還有另一種看待目標價的方式,那就是查看分析師提出的目標價範圍,因爲估計範圍很大可能表明對業務可能結果有不同看法。目前,最看好的分析師認爲科學應用國際的價值爲每股155美元,而最看淡者認爲每股價值爲124美元。鑑於這麼狹窄的估值區間,分析師顯然對他們認爲這家企業的價值有類似的看法。

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's pretty clear that there is an expectation that Science Applications International's revenue growth will slow down substantially, with revenues to the end of 2026 expected to display 2.4% growth on an annualised basis. This is compared to a historical growth rate of 3.2% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 6.2% annually. Factoring in the forecast slowdown in growth, it seems obvious that Science Applications International is also expected to grow slower than other industry participants.

現在來看看更大的圖景,了解這些預測的一種方式是看其與過去表現和行業增長預期的比較。很明顯,預期到2026年底,科學應用國際的營收增長將大幅放緩,預計將以年均2.4%的增長率增長。這與過去五年的歷史增長率3.2%相比。與行業內的其他公司(根據分析師預測)相比,預計其年均營收增長率爲6.2%。考慮到增長放緩的預期,科學應用國際也被預期增長速度比其他行業參與者慢。

The Bottom Line

最重要的事情是分析師增加了它對下一年每股虧損的估計。令人欣慰的是,營收預測未發生重大變化,業務仍有望比整個行業增長更快。共識價格目標穩定在28.50美元,最新估計不足以對價格目標產生影響。

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at US$143, with the latest estimates not enough to have an impact on their price targets.

最明顯的結論是,最近業務前景沒有發生重大變化,分析師們保持其盈利預測穩定,與先前估計一致。在積極的一面,營業收入預測沒有發生重大變化;儘管預測表明它們的表現將不如整個行業。共識價格目標保持在143美元,最新估算數據不足以對他們的價格目標產生影響。

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Science Applications International analysts - going out to 2027, and you can see them free on our platform here.

話雖如此,公司盈利的長期軌跡比明年更重要。我們有來自多家science applications international分析師的截至2027年的估算數據,您可以在我們的平台上免費查看。

Even so, be aware that Science Applications International is showing 2 warning signs in our investment analysis , you should know about...

儘管如此,請注意在我們的投資分析中,science applications international 顯示了2個警示信號,您應當了解一下...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論